Cargando…
Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
BACKGROUND: Achievement of pathologic complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and disease-free survival. The aim of present study was to identify clinical and pathological factors associated with achieving pC...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249452/ https://www.ncbi.nlm.nih.gov/pubmed/30255695 http://dx.doi.org/10.22034/APJCP.2018.19.9.2423 |
_version_ | 1783372752613277696 |
---|---|
author | Sasanpour, Pegah Sandoughdaran, Saleh Mosavi-Jarrahi, Alireza Malekzadeh, Mona |
author_facet | Sasanpour, Pegah Sandoughdaran, Saleh Mosavi-Jarrahi, Alireza Malekzadeh, Mona |
author_sort | Sasanpour, Pegah |
collection | PubMed |
description | BACKGROUND: Achievement of pathologic complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and disease-free survival. The aim of present study was to identify clinical and pathological factors associated with achieving pCR in Iranian breast cancer patients receiving NAC. METHODS: A retrospective review of all breast cancer patients treated with neoadjuvant chemotherapy between April 2012 and September 2016 at our institution was performed; 207 cases were evaluable for analysis. pCR was defined as having no residual invasive tumor in the breast surgical specimen removed following neoadjuvant therapy. RESULTS: In univariate analysis, factors associated with pCR were age less than 35 years (p = 0.03), absence of Lymphovascular invasion (LVI) (p = 0.002) and negative hormone receptor status (p = 0.003). Hormone receptor status (P = 0.01; OR, 2.45; CI, 1.20 - 4.99) and LVI (P = 0.001; OR, 0.22; CI, 0.10 - 0.46) remained predictive variables in multivariate analysis after correction for the other variables. CONCLUSIONS: In conclusion, the results of this study suggests that presence of Lymphovascular invasion and positive hormone receptor status are associated with poorer response to neoadjuvant chemotherapy in breast cancer patients. |
format | Online Article Text |
id | pubmed-6249452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-62494522018-12-07 Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients Sasanpour, Pegah Sandoughdaran, Saleh Mosavi-Jarrahi, Alireza Malekzadeh, Mona Asian Pac J Cancer Prev Research Article BACKGROUND: Achievement of pathologic complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is associated with both overall survival and disease-free survival. The aim of present study was to identify clinical and pathological factors associated with achieving pCR in Iranian breast cancer patients receiving NAC. METHODS: A retrospective review of all breast cancer patients treated with neoadjuvant chemotherapy between April 2012 and September 2016 at our institution was performed; 207 cases were evaluable for analysis. pCR was defined as having no residual invasive tumor in the breast surgical specimen removed following neoadjuvant therapy. RESULTS: In univariate analysis, factors associated with pCR were age less than 35 years (p = 0.03), absence of Lymphovascular invasion (LVI) (p = 0.002) and negative hormone receptor status (p = 0.003). Hormone receptor status (P = 0.01; OR, 2.45; CI, 1.20 - 4.99) and LVI (P = 0.001; OR, 0.22; CI, 0.10 - 0.46) remained predictive variables in multivariate analysis after correction for the other variables. CONCLUSIONS: In conclusion, the results of this study suggests that presence of Lymphovascular invasion and positive hormone receptor status are associated with poorer response to neoadjuvant chemotherapy in breast cancer patients. West Asia Organization for Cancer Prevention 2018 /pmc/articles/PMC6249452/ /pubmed/30255695 http://dx.doi.org/10.22034/APJCP.2018.19.9.2423 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Research Article Sasanpour, Pegah Sandoughdaran, Saleh Mosavi-Jarrahi, Alireza Malekzadeh, Mona Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients |
title | Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients |
title_full | Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients |
title_fullStr | Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients |
title_full_unstemmed | Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients |
title_short | Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients |
title_sort | predictors of pathological complete response to neoadjuvant chemotherapy in iranian breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249452/ https://www.ncbi.nlm.nih.gov/pubmed/30255695 http://dx.doi.org/10.22034/APJCP.2018.19.9.2423 |
work_keys_str_mv | AT sasanpourpegah predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients AT sandoughdaransaleh predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients AT mosavijarrahialireza predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients AT malekzadehmona predictorsofpathologicalcompleteresponsetoneoadjuvantchemotherapyiniranianbreastcancerpatients |